möglich sobald bei der ZB eingereicht worden ist.
Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
Oncotarget 6, 4663-4676 (2015)
In addition to local cytotoxic activity, radiotherapy may also elicit local and systemic antitumor immunity, which may be augmented by immunotherapeutic agents including Toll-like receptor (TLR) 7/8 agonists. Here, we investigated the ability of 3M-011 (854A), a TLR7/8 agonist, to boost the antigen-presenting activity of dendritic cells (DC) as an adjuvant to radiotherapy. The combined treatment induced marked local and systemic responses in subcutaneous and orthotopic mouse models of colorectal and pancreatic cancer. In vitro cytotoxicity assays as well as in vivo depletion experiments with monoclonal antibodies identified NK and CD8 T cells as the cell populations mediating the cytotoxic effects of the treatment, while in vivo depletion of CD11c+ dendritic cells (DC) in CD11c-DTR transgenic mice revealed DC as the pivotal immune hub in this setting. The specificity of the immune reaction was confirmed by ELISPOT assays. TLR7/8 agonists therefore seem to be potent adjuvants to radiotherapy, inducing strong local and profound systemic immune responses to tumor antigens released by conventional therapy.
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Tlr7/8 Ligand ; Colorectal Cancer ; Immunotherapy ; Pancreatic Cancer ; Radiotherapy
ISSN (print) / ISBN 1949-2553
Quellenangaben Band: 6, Heft: 7, Seiten: 4663-4676
Verlag Impact Journals LLC
Institut(e) Institute for Pancreatic Beta Cell Research (IPI)